A case of neural cell adhesion molecule-positive peripheral T-cell lymphoma associated with human T-cell lymphotrophic virus type 1 showing an unusual involvement of the gastrointestinal tract during the course of the disease

Hayashi, Kayoko; Nakamura, Shigeo; Koshikawa, Takashi; Kitoh, Kuniyoshi; Koike, Koichi; Komatsu, Hirokazu; Kuroda, Makoto; Kasahara, Masao; Ueda, Ryuzo; Suchi, Taizan

doi:10.1016/0046-8177(94)90045-0

Cited by 11 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(12) CD56 can also be expressed in certain neoplastic cells such as AML cells, (10,13-17) acute myeloid/NK cell leukemia (myeloid/NK AL), (17) ALL (10) and lymphoma. (11,18-21) …”

Section: Introductionmentioning

confidence: 99%

The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia

Alegretti

Bittar

Bittencourt

et al. 2011

Rev. Bras. Hematol. Hemoter.

View full text Add to dashboard Cite

BackgroundThe expression of CD56 is considered a bad prognostic factor for overall survival, lower rates or short complete remission and extramedullary invasion but the results are controversial. The importance of validating new prognostic parameters in acute leukemias was the reason to investigate the CD56 expression in blast cells of patients with acute myeloid leukemia.MethodsA cohort of 48 patients treated at Hospital de Clinicas de Porto Alegre and diagnosed with acute myeloid leukemia as classified by the French-American-British group (FAB) criteria using cell morphology, cytochemistry and flow cytometry were evaluated.ResultsEight cases (16.7%) were CD56 positive without correlation to age or gender. The highest incidence of CD56 positivity was in FAB subtypes M4 and M5. The death rate during induction was not significantly different between patients with and without CD56 expression (62.5% vs. 27.5%; p-value = 0.097). However, patients that expressed CD56 had significantly lower overall survival than those who did not (mean 4.0 months vs. 14.5 months; p-value = 0.03).ConclusionsThe data suggest that expression of CD56 in acute myeloid leukemia may be indicative of poor prognosis because it is associated with a shorter overall survival. The death rate during induction was not significantly different despite an apparent difference in proportions between groups.

show abstract

“…(12) CD56 can also be expressed in certain neoplastic cells such as AML cells, (10,13-17) acute myeloid/NK cell leukemia (myeloid/NK AL), (17) ALL (10) and lymphoma. (11,18-21) …”

Section: Introductionmentioning

confidence: 99%

The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia

Alegretti

Bittar

Bittencourt

et al. 2011

Rev. Bras. Hematol. Hemoter.

View full text Add to dashboard Cite

show abstract

“…It can be diagnosed by characteristic clinicopathological features and the presence of integrated proviral HTLV-1 DNA in tumour cells with a helper/inducer (CD4 + ) phenotype [19,21]. In rare cases, ATLL cells express CD8 (cytotoxic/suppressor) or CD56 (natural killer [NK]-associated) antigens [4,6,9].…”

Section: Introductionmentioning

confidence: 99%

Absence of cytotoxic molecules in CD8- and/or CD56-positive adult T-cell leukaemia/lymphoma

et al. 1999

View full text Add to dashboard Cite

Adult T-cell leukaemia/lymphoma (ATLL) cells usually exhibit a CD4+ (helper/inducer) phenotype (CD4+/8-/56-), and only a minority of tumours express the CD8 (cytotoxic/suppressor) or CD56 (natural killer [NK]-associated) antigens. TIA-1 is a cytotoxic granule-associated protein expressed in NK cells and cytotoxic T lymphocytes (CTLs). Granzyme B, perforin and Fas ligand (FasL) are also expressed in activated CTLs and NK cells. To clarify the cytotoxic potential of ATLL cells, immunohistochemistry was performed in CD8+ and/or CD56+ ATLL cells, using anti-TIA-1, anti-granzyme B, anti-perforin and anti-FasL antibodies. We studied nine cases of CD8+ and/or CD56+ ATLL, all of which exhibited monoclonal integration of human T-cell leukaemia virus type 1 (HTLV-1) proviral DNA. Four cases exhibited a CD8+/CD56- phenotype, four others had a CD8-/CD56+ phenotype, and one was CD8+/CD56+. All but one case also expressed the surface antigens CD3, TCR alpha beta, and CD4. Expression of granzyme B and TIA-1 were demonstrated in three and two cases, respectively, but none expressed perforin or FasL. In the control study, 10 cases with typical CD3+/4+/8-/56- ATLL demonstrated no expression of those cytotoxic-associated proteins. Our findings suggest that CD8 and/or CD56 positivity probably confer(s) no cytotoxic function on ATLL cells, and it is possible that CD8 and CD56 may be simply aberrant surface markers in ATLL.

show abstract

“…EBV and human herpesvirus-6 are not detectable. Human T cell lymphotropic virus type I (HTLV-I) was found in one case, 9 while others [10][11][12] failed to detect this virus. In general, (latent) viral infection does not seem to play an important role in the pathogenesis of this disease.…”

mentioning

confidence: 99%

What is CD4+CD56+ malignancy and how should it be treated?

Reimer

Rüdiger

Kraemer

et al. 2003

Bone Marrow Transplant

152

170

View full text Add to dashboard Cite

Summary:CD4+CD56+ malignancy is a rare neoplasm with a typical clinical pattern, an aggressive course and high early relapse rate despite good initial response to chemotherapy. In this review, the impact of different therapeutic approaches on clinical outcome has been studied. We evaluated 91 published cases and our own six patients in terms of clinical features, immunophenotype/ cytogenetics and treatment outcome. Treatment was divided into four groups: (A) chemotherapy less intensive than CHOP; (B) CHOP and CHOP-like regimens; (C) therapy for acute leukemia; (D) allogeneic/autologous stem cell transplantation. The median overall survival was only 13 months for all patients. Patients with skinrestricted disease showed no difference in the overall survival from patients with advanced disease (17 and 12 months, respectively). Age X60 years was a negative prognostic factor. Age-adjusted analysis revealed improved survival after high-dose chemo/radiotherapy followed by allogeneic stem cell transplantation when performed in first complete remission. This therapeutic approach should be recommended for eligible patients with CD4+CD56+ malignancy. For older patients the best treatment option is still unknown.

show abstract

A case of neural cell adhesion molecule-positive peripheral T-cell lymphoma associated with human T-cell lymphotrophic virus type 1 showing an unusual involvement of the gastrointestinal tract during the course of the disease

Cited by 11 publications

References 10 publications

The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia

The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia

Absence of cytotoxic molecules in CD8- and/or CD56-positive adult T-cell leukaemia/lymphoma

What is CD4+CD56+ malignancy and how should it be treated?

Contact Info

Product

Resources

About